[go: up one dir, main page]

WO1996012734A1 - Preparation vaccinale obtenue a partir de bacteries cultivees dans des milieux riches en fer - Google Patents

Preparation vaccinale obtenue a partir de bacteries cultivees dans des milieux riches en fer Download PDF

Info

Publication number
WO1996012734A1
WO1996012734A1 PCT/SE1995/001251 SE9501251W WO9612734A1 WO 1996012734 A1 WO1996012734 A1 WO 1996012734A1 SE 9501251 W SE9501251 W SE 9501251W WO 9612734 A1 WO9612734 A1 WO 9612734A1
Authority
WO
WIPO (PCT)
Prior art keywords
vaccine
bacteria
iron
effective against
vaccine according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/SE1995/001251
Other languages
English (en)
Inventor
Andrew Cartner Barnes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EWOS AB
Original Assignee
EWOS AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EWOS AB filed Critical EWOS AB
Priority to AU38210/95A priority Critical patent/AU3821095A/en
Publication of WO1996012734A1 publication Critical patent/WO1996012734A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Definitions

  • the present invention relates to improved vaccines and the preparation of vac- cines active against bacterial diseases, whereby a pathogenic bacteria is culti ⁇ vated, and a vaccine is prepared from the cultivated bacteria or its expression components present in the growth medium.
  • NaCI (designated TSB2) was prepared and aliquoted 250 ml each into 500 ml 5 conical flasks, which were autoclaved at 121°C for 15 min. The flasks were allowed to cool whereupon the following filter sterilized additions were made aseptically into separate flasks:

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention se rapporte à un vaccin amélioré et à son procédé de préparation. Ce vaccin amélioré contre les maladies d'origine bactérienne est obtenu d'une culture de bactéries produisant une bactérine dans un milieu nutritif contenant des sources de fer à des niveaux dépassant ceux des milieux généralement utilisés jusqu'ici à cet effet. Le vaccin est ensuite préparé à partir des bactéries cultivées et/ou de leurs parties constitutives et/ou de constituants exprimés par ces bactéries et présents dans le milieu de croissance.
PCT/SE1995/001251 1994-10-24 1995-10-23 Preparation vaccinale obtenue a partir de bacteries cultivees dans des milieux riches en fer Ceased WO1996012734A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU38210/95A AU3821095A (en) 1994-10-24 1995-10-23 Vaccine preparation recovered from bacteria grown in iron-rich media

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9403636-5 1994-10-24
SE9403636A SE9403636D0 (sv) 1994-10-24 1994-10-24 Vaccine preparation

Publications (1)

Publication Number Publication Date
WO1996012734A1 true WO1996012734A1 (fr) 1996-05-02

Family

ID=20395723

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1995/001251 Ceased WO1996012734A1 (fr) 1994-10-24 1995-10-23 Preparation vaccinale obtenue a partir de bacteries cultivees dans des milieux riches en fer

Country Status (3)

Country Link
AU (1) AU3821095A (fr)
SE (1) SE9403636D0 (fr)
WO (1) WO1996012734A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2115550A1 (es) * 1996-10-14 1998-06-16 Univ Santiago Compostela Vacuna anti-pasteurella piscicida (di)para la prevencion de la enfermedad pasteurelosis en dorada y lubina y procedimiento de obtencion. .
WO2001010459A3 (fr) * 1999-08-07 2001-05-10 Aqua Health Europ Ltd Vaccin
WO2005014629A3 (fr) * 2003-07-29 2005-11-17 Novartis Ag Proteine issue de photobacterium damselae et utilisation de celle-ci
US12403187B2 (en) 2018-12-31 2025-09-02 Bellevacc As Bacterial vaccine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF GENERAL MICROBIOLOGY, Volume 138, 1992, R.L. DAVIES et al., "Outer-Membrane Protein and Lipopolysaccharide Variation in Pasteurella Haemolytica Serotype A1 Under Different Growth Conditions", pages 909-922. *
VETERINARY MICROBIOLOGY, Volume 41, 1994, DONNA M. GATEWOOD et al., "Growth-Condition Dependent Expression of Pasteurella Haemolytica A1 Outer Membrane Proteins, Capsule and Leukotoxin", pages 221-233. *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2115550A1 (es) * 1996-10-14 1998-06-16 Univ Santiago Compostela Vacuna anti-pasteurella piscicida (di)para la prevencion de la enfermedad pasteurelosis en dorada y lubina y procedimiento de obtencion. .
WO2001010459A3 (fr) * 1999-08-07 2001-05-10 Aqua Health Europ Ltd Vaccin
JP2003506412A (ja) * 1999-08-07 2003-02-18 ノバルテイス・アクチエンゲゼルシヤフト ワクチン
JP2011207888A (ja) * 1999-08-07 2011-10-20 Novartis Ag ワクチン
JP4831905B2 (ja) * 1999-08-07 2011-12-07 ノバルティス アーゲー ワクチン
WO2005014629A3 (fr) * 2003-07-29 2005-11-17 Novartis Ag Proteine issue de photobacterium damselae et utilisation de celle-ci
JP2007526755A (ja) * 2003-07-29 2007-09-20 ノバルティス アクチエンゲゼルシャフト フォトバクテリウム・ダムセラの蛋白質およびその使用
JP4881731B2 (ja) * 2003-07-29 2012-02-22 ノバルティス アーゲー フォトバクテリウム・ダムセラの蛋白質およびその使用
US8197827B2 (en) 2003-07-29 2012-06-12 Novartis Ag Protein from Photobacterium damselae and use thereof
US8343507B2 (en) 2003-07-29 2013-01-01 Novartis Ag Protein from Photobacterium damselae and use thereof
US12403187B2 (en) 2018-12-31 2025-09-02 Bellevacc As Bacterial vaccine

Also Published As

Publication number Publication date
SE9403636D0 (sv) 1994-10-24
AU3821095A (en) 1996-05-15

Similar Documents

Publication Publication Date Title
CA1139663A (fr) Vaccin contre la diarrhee causee par e. coli
CN1270838A (zh) 用于疫苗中的佐剂
JPH0840932A (ja) スタフイロコッカス属菌感染症の予防ワクチン及び治療用抗体並びにそれの製造法
US5616328A (en) Method of preparing gram-negative bacterial vaccines
US4285931A (en) E. coli enterotoxin vaccine for veterinary and human use
US4220584A (en) E. coli enterotoxin vaccine for veterinary and human use
JP2718518B2 (ja) マイコプラズマワクチン
WO1996012734A1 (fr) Preparation vaccinale obtenue a partir de bacteries cultivees dans des milieux riches en fer
US5576003A (en) Ornithobacterium rhinotracheale vaccine and method of immunization
EP0374178A1 (fr) Procede de preparation de vaccins veterinaires acellulaires contre des bacilles pathogenes non-enteriques gram-negatifs.
CN104138597A (zh) 一种鳗弧菌二价疫苗及其制备和使用方法
US4136181A (en) Vaccines against oedema disease of piglets
GB2023420A (en) Preparations containing antigen from pasteurella haemolytica
US4465665A (en) Detoxified E. coli neurotoxin, preparation thereof and immunological preparations containing it
CN100563708C (zh) 具有交叉保护力的革兰氏阴性病原菌灭活疫苗的制备方法
RU2109519C1 (ru) Способ изготовления вакцины против некробактериоза животных
JP2721218B2 (ja) ブタ赤痢ワクチン
Matsuo et al. Suppression of immunoresponses to Haemophilus gallinarum with nonviable Mycoplasma gallisepticum in chickens
Cameron The significance of the endotoxin and pyogenic factor of Corynebacterium pseudotuberculosis in immunity
RU1149467C (ru) Вакцина против колибактериоза молодняка крупного рогатого скота и овец
JP4081515B2 (ja) 魚類の腸球菌症用ワクチン
US3980523A (en) Method of propagating microorganisms
EP0563288B1 (fr) Immunopotentialisation de vaccins, notamment de vaccins contre la pleuropneumonie porcine
RU1149466C (ru) Вакцина против колибактериоза поросят
RU2018322C1 (ru) Вакцина против рожи свиней

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA CN FI JP MX NO US VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase